Lakefront Biotherapeutics reports September 21 to 25 buyback, holdings reach 1,633,594 shares

Lakefront Biotherapeutics NV disclosed another weekly share repurchase under the buyback program it announced on June 9, 2026, in a Form 6-K filed after the latest purchase window closed.

From September 21 to 25, 2026, Lakefront repurchased 106,060 shares for a total of 2,795,740.67 euros, at an average price of 26.36 euros. As of market close on September 25, it held 1,633,594 of its own ordinary shares.

Earlier weekly disclosures reported these purchases and holdings:

September 14 to 18: 108,679 shares for 2,608,832.08 euros, averaging 24.00 euros; holding 1,527,534 September 7 to 11: 125,517 shares for 3,005,545.12 euros, averaging 23.95 euros; holding 1,418,855 August 31 to September 4: 132,014 shares for 3,279,463.42 euros, averaging 24.84 euros; holding 1,293,338 August 24 to 28: 127,796 shares for 3,218,710.15 euros, averaging 25.19 euros; holding 1,161,324 August 17 to 21: 117,471 shares for 2,866,035.10 euros, averaging 24.40 euros; holding 1,033,528 August 10 to 14: 107,871 shares for 2,604,002.56 euros, averaging 24.14 euros; holding 916,057 August 3 to 7: 103,970 shares for 2,409,901.40 euros, averaging 23.18 euros; holding 808,186

In each window, an independent financial intermediary executed the purchases under a discretionary mandate, across the XAMS, TQEX, AQEU and CEUX venues.

Lakefront describes itself as a clinical-stage biotechnology company focused on immunology and inflammation. Its lead program is gamgertamig, a BCMAxCD3 T-cell engager in development for autoimmune diseases.